RISK FACTORS FOR PSYCHIATRIC SYMPTOMS IN SUBSTANCE ABUSERS
Keywords:
Substances abuse, Psychiatric symptoms, Risk factorsAbstract
The prevalence of mental health issues resulting from substance addiction is a common concern in Thai society, with potential for prevention and mitigation by addressing associated risk factors. This study aimed to assess these risk factors in predicting the emergence of psychiatric symptoms among substance abusers. Employing analytical research methods, a case-control study design was utilized. Cases comprised 1,000 substance abusers diagnosed with mental illness and undergoing treatment in government facilities nationwide, selected through a stratified multistage sampling approach. A control group consisted of substance abusers receiving treatment for drug addiction without diagnosed mental illness in the same facilities. Data collection was conducted using a structured interview form, with analysis performed through descriptive statistics, chi-square tests, and multiple logistic regression.
The study outcomes revealed eight significant factors contributing to the onset of psychotic symptoms due to drug consumption. These factors included income (AOR 1.874), methamphetamine tablet (YABA) usage (AOR 6.950), methamphetamine crystal (ICE) consumption (AOR 4.241), cannabis usage (AOR 3.508), ecstasy usage (AOR 5.983), ketamine usage (AOR 5.569), consumption of non-prescription medicine (AOR 2.245), and usage of polydrug (AOR 1.441).
Downloads
References
United Nations Office on Drugs and Crime (UNODC). World drug report 2019. Vienna: United Nations publication; 2019.
Merlin MD. Archaeological evidence for the tradition of psychoactive plant use in the old world. Economic Botany 2003; 57(3): 295-323.
Sullivan RJ, Hagen EH. Psychotropic substance-seeking: Evolutionary pathology or adaptation? Addiction 2002; 97(4): 389-400.
Department of Fine Arts. The “Tra Sam Duang” Laws. Bangkok: Veteran printing house; 1978. [in Thai].
Kanato M, Leyatikul P, Wonguppa R. Impacts of Medical Cannabis Law in Thailand. ONCB Journal 2020; 36(2): 27-36.
Poshyachinda V. Heroin in Thailand. in the 4th Anniversary of the Office of the Narcotics Control Board. Bangkok: Office of the Prime Minister; 1980; 56-87.
Poshyachinda V, Srisurapanont M, Perngparn, U. Amphetamine type stimulants epidemic in Thailand: a country profile. In WHO meeting on amphetamine, MDMA, and other psycho stimulants phase II. Bangkok, Thailand; 1999. 22-26.
Poshyachinda V, Phittayanon P, Simasatitkul V, Perngparn U. Stimulant use, abuse, and dependence in Thailand. Alcohol and drugs perspectives, prevention and control-Asia Pacific region. Sri Lanka: Alcohol and Drug Information Centre. 1998; 77-106.
Wonguppa R, Kanato M. The prevalence and associated factors of new psychoactive substance use: A 2016 Thailand national household survey. Addict Behav Rep 2018; 7: 111-115
Kanato M, Leyatikul P, Wonguppa R. Cannabis Situation among the Thai Youth after Law Amendment. ONCB Journal 2022; 36(2): 27-36.
United Nations Office on Drugs and Crime (UNODC). World drug report 2023. Vienna: United Nations publication; 2023.
Kanato M, Sarasiri R, Leyatikul P. (Eds.) ASEAN DRUG MONITORING REPORT 2022. Bangkok: ASEAN Narcotics Cooperation Center; 2023.
Kanato M, Leyatikul P. Size Estimation of Substances Users Population in Thailand 2019. ONCB Journal 2020; 36(2): 37-48.
Office of Secretary of National Addiction treatment & Rehabilitation Committee, Ministry of Public Health. Statistics on Addiction Treatment & Rehabilitation [online] 2020 [cited 2024 March 7]. Available from: https://ncmc.moph.go.th/home/index/dash [in Thai].
WHO. Management of substance abuse [online] 2021 [cited 2021 Jan 21]. Available from: https://www. Who. int/substance_abuse/facts/ATS/en/
McCrady BS, Epstein EE. Addictions: A comprehensive guidebook. Oxford University Press; 2013.
Grant KM, LeVan TD, Wells SM, Li M, Stoltenberg SF, Gendelman HE, et al. Methamphetamine - associated psychosis. Journal of Neuroimmune Pharmacology 2012; 7(1): 113-139.
Schlesselman JJ. Sample size requirements in cohort and case-control studies of disease. American journal of epidemiology1974; 99(6): 381-384.
Srisurapanont M, Ali R, Marsden J, Sunga A, Wada K, Monteiro M. Psychotic symptoms in methamphetamine psychotic in-patients. International Journal of Neuropsycho pharmacology 2003; 6(4); 347-352.
Arunogiri S, Foulds JA, McKetin R, Lubman DI. A systematic review of risk factors for methamphetamine-associated psychosis. Australian & New Zealand Journal of Psychiatry 2018; 52(6): 514-529.
Callaghan RC, Cunningham JK, Allebeck P, Arenovich T, Sajeev G, Remington GE, et al. Methamphetamine use and schizophrenia: a population-based cohort study in California. American Journal of Psychiatry 2012; 169(4): 389-396.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Community Health Development Quarterly Khon Kaen University
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Articles in this journal are copyrighted by the x may be read and used for academic purposes, such as teaching, research, or citation, with proper credit given to the author and the journal.use or modification of the articles is prohibited without permission.
statements expressed in the articles are solely the opinions of the authors.
authors are fully responsible for the content and accuracy of their articles.
other reuse or republication requires permission from the journal."
